FRI0398 Adipokines, Tumor Necrosis Factor and its Receptors in Systemic Lupus Erythematosus

BackgroundAdipokines, tumor necrosis factor α(TNFα)and its receptors, participate in the regulation of the immune system and inflammation in immune disease (1). The role and interactions between those cytokines and systemic lupus erythematosus (SLE) characteristics and treatment is poorly studied and understood.ObjectivesTo analyze the association of adipokines and TNFα and its receptors with clinical, laboratory and treatment-related manifestations of SLE, and to investigate the correlation between adipokines and the TNF system.MethodsA 136 women with SLE, aged >18 years old, were included in this cross-sectional study. Disease activity was measured by modified SLEDAI-2K and irreversible cumulative damage by SLICC-ACR damage index. Serum concentrations of TNFα, soluble TNFα receptors 1 (sTNFR1) and 2 (sTNFR2) and adipokines were analyzed by ELISA kits.ResultsThe median of age was 41.5 (33.0-49.7) years old and of disease duration was 11.3 (7.8-15.8) years. 105 (77.2%) participants were nonwhite and 67 (49.3%) were postmenopausal. The median of cumulative dose of prednisone was 36.5 (22.9-51.1) g, and of daily dose of prednisone was 5.0 (0.0-10.0) mg/day. The median of disease activity and of damage index scores were 0 (0-4) and 2 (1-3). Higher levels of sTNFR1 and sTNFR2 were associated with nephritis (p